Evidence map›Paper›PMID 40402461›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2025

Engineered CAR-NK Cells for Cancer Immunotherapy: Lentiviral-Based CAR Transduction of NK-92 Cells.

Dayane Schmidt, Mariane Cariati Tirapelle, Sima Ebrahimabadi, Alison Felipe Bordini Biggi, Matheus Henrique Dos Santos, Mara Elisama da Silva-Januário, Virginia Picanço E Castro

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Dayane SchmidtCenter for Cell-Based Therapy - CTC, Regional Blood Center of Ribeirão Preto, University of São Paulo - USP, Ribeirão Preto, São Paulo, Brazil.
Mariane Cariati TirapelleCenter for Cell-Based Therapy - CTC, Regional Blood Center of Ribeirão Preto, University of São Paulo - USP, Ribeirão Preto, São Paulo, Brazil.
Sima EbrahimabadiCenter for Cell-Based Therapy - CTC, Regional Blood Center of Ribeirão Preto, University of São Paulo - USP, Ribeirão Preto, São Paulo, Brazil.
Alison Felipe Bordini BiggiCenter for Cell-Based Therapy - CTC, Regional Blood Center of Ribeirão Preto, University of São Paulo - USP, Ribeirão Preto, São Paulo, Brazil.
Matheus Henrique Dos SantosCenter for Cell-Based Therapy - CTC, Regional Blood Center of Ribeirão Preto, University of São Paulo - USP, Ribeirão Preto, São Paulo, Brazil.
Mara Elisama da Silva-JanuárioCenter for Cell-Based Therapy - CTC, Regional Blood Center of Ribeirão Preto, University of São Paulo - USP, Ribeirão Preto, São Paulo, Brazil. mara.silva@hemocentro.fmrp.usp.br.
Virginia Picanço E CastroCenter for Cell-Based Therapy - CTC, Regional Blood Center of Ribeirão Preto, University of São Paulo - USP, Ribeirão Preto, São Paulo, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chimeric antigen receptor (CAR)-T cell therapy has emerged as a groundbreaking immunotherapeutic approach to cancer treatment. However, despite its remarkable results, challenges persist, such as manufacturing complexity, side effects, and cost. Allogeneic therapies offer potential solutions to these challenges by enhancing accessibility, reducing cost, and increasing scalability. Due to their innate cytotoxicity and reduced risks of side effects to the patients, natural killer cells are an up-and-coming option for allogeneic CAR therapy. The NK-92 cell line use allows large-scale expansion suitable for clinical grade applications, providing a uniform and highly cytotoxic source. Nevertheless, gene delivery using viral vectors is still an obstacle related to CAR-NK therapies due to their natural antiviral activity. Thus, the present protocol offers an efficient approach for CAR-NK-92 cell generation via lentiviral transduction, thereby advancing the potential of this promising cancer therapy.

Indexed as

Immunotherapy, AdoptiveKiller Cells, NaturalLentivirusNeoplasmsReceptors, Chimeric AntigenTransduction, GeneticCell EngineeringCell LineCell Line, TumorGenetic VectorsHumansReceptors, Chimeric AntigenCAR-NKChimeric antigen receptorImmunotherapyLentiviral transductionNK-92 cellsViral vector

Identifiers

PMID40402461

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.